Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Chimeric antigen receptor (CAR) T-cell immunotherapy shows promise for solid tumors but faces challenges like T-cell dysfunction.
• Lenalidomide is an immunomodulator with potential to enhance CAR T-cell efficacy.

Purpose of the Study:

• To investigate the effects of lenalidomide on CAR T-cell functions, including cytotoxicity, cytokine secretion, and proliferation.
• To explore lenalidomide's impact on CD133-specific and HER2-specific CAR T-cells against relevant cancer cell lines.

Main Methods:

• Preparation of CD133-specific and HER2-specific CAR T-cells.
• Functional assays using human glioma (U251 CD133-OE) and breast cancer (MDA-MB-453) cell lines.
• Assessment of CAR T-cell cytotoxicity, cytokine secretion, and proliferation in the presence of lenalidomide.

Main Results:

• Lenalidomide significantly promoted CD133-CAR T-cell cytotoxicity, cytokine secretion, and proliferation against CD133-overexpressing glioma cells.
• Lenalidomide enhanced HER2-CAR T-cell cytotoxicity and cytokine secretion against breast cancer cells, with no significant effect on proliferation.
• Lenalidomide's mechanism may involve inducing degradation of transcription factors Ikaros and Aiolos.

Conclusions:

• Lenalidomide can improve the function of CAR T-cells, potentially overcoming T-cell exhaustion in solid tumor treatment.
• Lenalidomide demonstrates efficacy in enhancing both CD133-CAR and HER2-CAR T-cell activity, suggesting broader applicability.
• The study identifies lenalidomide as a potential therapeutic agent to augment CAR T-cell immunotherapy for solid malignancies.